• Company
  • Technology
  • Team
    • Board of Directors
    • Management
    • Extended Management
    • Project Management
  • Partners & Advisors
    • Preclinical Research
    • Clinical Research
    • Strategic Investment
  • Investors
  • News
    • Company News
    • Scientific Publications
  • Contact

Scientific Publications

High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters

30 October 2024

Promising Next-Generation SARS-CoV-2 Live Vaccine Demonstrates Remarkable Safety, Protection, and Immunity Profile in Pre-Clinical Studies

14 August 2024

An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission

25 February 2024

A non-transmissible live attenuated SARS-CoV-2 vaccine

26 May 2023

Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters

3 April 2023

Live-attenuated vaccines as a promising tool to defeat Covid-19

21 October 2022

Synthetically recoded virus sCPD9 - A tool to accelerate SARS-CoV-2 research under biosafety level 2 conditions

13 August 2022

Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta)

1 December 2021

Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding

19 July 2021
contact@rocketvax.com +41 61 561 54 21

RocketVax AG

c/o Swiss Rockets AG

Lautengartenstrasse 6, 4052 Basel

Switzerland

Contact Us

Your Name*

Your Email*

Subject

Message

Privacy Policy Legal DisclaimerManage Cookies
© Copyright 2025. RocketVax AG. All rights reserved